RUNX1 (Runt-related transcription factor 1) gene, also known as AML1, maps at 21q22.3 and encodes a transcription factor crucial for normal hematopoiesis. It is frequently involved in gene fusions resulting from 35 different translocations 1 (http://cgap.nci.nih.gov/Chromosomes/Mitelman). The fusion transcript 5 0 RUNX1/3 0 CBFA2T1 (alias MTG8 or ETO), resulting from a t(8;21)(q22;q22), is present in approximately 30% of acute myeloid leukemia M2 patients (AML-M2). 2 Other frequent fusions, in adult AML, are the t(16;21)(q24;q22), occurring in AML-M1/M2 patients and generating a 5 0 RUNX1/3 0 CBFA2T3 chimera, 4 and the t(3;21)(q26;q22), found in both de novo and secondary AML, fusing RUNX1 to MDS1, RPL22L1 (also known as EAP) or EVI1. 1 In two AML cases showing a t(20;21) translocation, the partner gene was not identified. 4, 5 We report here the characterization of two chimeric transcripts identified in AML translocation cases involving CBFA2T2 (core-binding factor, runt domain, a subunit; translocated to, 2), an ETO homologous gene on chromosome 20, and C20orf112.
Case 1
A 69-year-old man was referred in July 1989 to the Department of Internal Medicine of the Hô pital Pasteur (Nice) because of sudden fatigue and weakness. Physical examination was normal. The blood count showed: white blood cells 18.9 Â 109/l with 87% blast cells; hemoglobin (Hb) 6.8g per 100 ml, and platelets 29 Â 109/l. The bone marrow (BM) was infiltrated by 65% blast cells with myeloid morphology and strong peroxydase activity, and showed marked dysplasia. In retrospect, a diagnosis of AML with multilineage dysplasia without preceding myelodysplastic syndrome, according to the WHO (World Health Organization) classification, can be made. No evidence of exposure to mutagenic agents was found. Treatment with low-dose cytosine arabinoside (Ara-C) followed by purine analogs failed to induce remission. In spite of the continuing medical support including blood products, the patient died 7 months after diagnosis.
R-banding analysis of tumor cells suggested a t(20;21) translocation. Reiterative fluorescence in situ hybridization (FISH) experiments using appropriate BAC clones first and then fosmids (complete list in Supplementary Table 1) disclosed that the segment 20q11.22-q13.33 was inserted, in opposite orientation, at 21q22.12. Combining the R-banding and FISH data, the karyotype was defined as follows: 46,XY,ins(21;20) (q22.12;q11.22q13.33) [5] /46,idem,del(7)(q22) [7] /46,XY [4] . Relevant FISH results are reported in Supplementary Figure 1 . They revealed that the breakpoint on chromosome 21 mapped within the intron VII of the RUNX1 gene, and that the breakpoint on chromosome 20 fell within the first intron of CBFA2T2. The inverted insertion juxtaposed CBFA2T2 to RUNX1 in the same transcriptional orientation (Supplementary Figures 2, 3) . The distal breakpoint on chromosome 20 disclosed a deletion of approximately 400 kb. As a result of the deletion, the 3 0 portion of RUNX1 was probably juxtaposed to the GATA5 (GATA-binding protein 5), but in opposite orientation (Supplementary Figures 2, 3) . The reverse transcriptase-PCR (RT-PCR) experiment using primers RUNX1-5newF (RUNX1 exon 6) and CBFA2T2-3R (CBFA2T2 exon 3) (sequences in Supplementary Table 2) yielded three amplification products of 928 bp, 640 bp and 448 bp (Figure 1a ). They were sequenced and named splicing variant type 1, 2 and 3, respectively. Splicing variant type 1 (Acc. No. GU086368) and 2 (Acc. No. GU070939) fused exon 7 of RUNX1 to exon 2 and exon 3 of CBFA2T2, respectively (Figure 1b Table  2 ) yielded a 1104-bp fragment (Acc. No. GU070945). Its sequence showed that chromosome 20 at nt 30 571 395 was fused to chromosome 21 at nt 35 097 123, with a one nt microhomology (C) (Figure 2c ). RT-PCR using RUNX1-5newF (exon 6) and C20orf112-8R (exon 8) primers (Supplementary Table 2 ) yielded two bands of 1060 and 868 bp (Figure 2d ), whose sequencing showed that they were two 5 0 RUNX1/3 0 C20orf112 splicing variants (Acc. Nos. GU070941 and GU070942, respectively), differing for the presence or absence of exon 7 of RUNX1. The two chimeric transcripts fused respectively exon 7, or exon 6, of RUNX1 to exon 6 of a transcript isoform of C20orf112 on der(20) (Figures 2e and f) . It is to be noted that the latter isoform is distinct with respect to the one that fuses to PAX5 in pediatric acute lymphoblastic leukemia (ALL). 6 RT-PCR using RUNX1-6R/C20orf112-4F primer combination (Supplementary Table 2 ) produced a single 639-bp fragment (Figure 2d ) whose sequence (Acc. No. GU070943) showed a fusion between exon 5 of C20orf112 to the exon 8 of RUNX1 on der(21) (Figures 2e and f) . No amplification products were obtained with forward primers specific for exons 1-3 of C20orf112, suggesting the exclusion of these exons from the chimera (data not shown). The full-length chimeric transcripts on der(20) and on der(21), obtained using appropriate primers (Supplementary Table 2 ), were sequenced and in silico translated. Long and short 5 0 RUNX1/3 0 C20orf112 transcript variants showed an Open Reading Frame (ORF) of 335 and 271 aminoacids, respectively, and both chimeric proteins showed the retention of the RHD and the loss of the C-terminal transactivation domain (RunxI) (Figure 2g ). The 5 0 C20orf112/ 3 0 RUNX1 transcript encoded an ORF of 273 amino acids, showing the retention of the RunxI domain and the loss of the RHD (Figure 2g ). RQ-PCR experiments revealed that exons 5-8 of RUNX1 were overexpressed with respect to the normal BM, while comparable to control AML cases (Supplementary Figure 4a) ; exons 4-8 of C20orf112 were remarkably overexpressed with respect to both calibrator and control cases (Supplementary Figure 4c) .
The 12 isoforms of RUNX1 can act as both transcriptional activators or repressors of target genes, depending on the type of proteins interacting with them.
1 RUNX1 chimeric proteins, retaining RHD and lacking the transcription activation domain, have a leukemogenic effect by acting as dominant negative inhibitors of wild-type RUNX1 in transcription activation. The genomic structure and aminoacidic sequence of CBFA2T2 are highly similar to the other two CBFA2T-family members (CBFA2T1 and CBFA2T3).
2,3 CBFA2T2 is known to bind to the RUNX1/CBFA2T1 complex and may be important in triggering leukemogenesis. Interestingly, it has been shown that each CBFA2T homolog has a distinct expression pattern in hematopoietic cells, depending on cell population and maturation, suggesting that they have a distinct role in hematopoietic differentiation. In the already described RUNX1/CBFA2T1 and RUNX1/CBFA2T3 fusion products, the transactivation domain of RUNX1 is replaced by almost the entire CBFA2T. The CBFA2T domains act in recruiting a co-repressor complex, composed of Nuclear hormone receptor CoRepressor (NCoR), mSin3A, Silencing Mediator of Retinoid and Thyroid hormone receptors (SMRT) and Histone DeACetylase (HDAC). As a result, RUNX1 target genes, normally activated by the wild-type RUNX1, are repressed. It has been recently shown that both wild-type CBFA2T and chimeric RUNX1/CBFA2T proteins show in vitro RNA-binding properties, suggesting novel scenarios in CBFA2T-mediated chromatin regulation. The high homology of the CBFA2T2 with respect to CBFA2T1 and CBFA2T3, strongly suggests that all the three chimeras resulting from their fusion with RUNX1 have a similar affect in leukemogenesis. In case 2, the two isoforms generated by the 5 0 RUNX1/3 0 C20orf112 retain the RUNX1 RHD domain, whereas the 5 0 C20orf112/RUNX13 0 transcript shows a ORF of 150 amino acids (data not shown), lacking the transactivation domain. We may speculate that C20orf112/RUNX1 chimera could bind to RUNX1 target genes, but are unable to regulate their transcription.
To the best of our knowledge, this is the first report in which RUNX1 chimeric genes resulting from rearrangements involving chromosomes 20 and 21 have been identified. It would be interesting to analyze additional AML cases showing t(20;21) to check their recurrence. In addition, according to our RQ-PCR results, both wild-type CBFA2T2 and C20orf112 are expressed at low levels in AML and normal BM, whereas the RUNX1/ C20orf112 and RUNX1/CBFA2T2 transcripts are expressed at higher levels than wild-type C20orf112 and CBFA2T2 genes in AML. This is probably because the expression of the fusion genes is driven, in both cases, by the RUNX1 promoter sequence.
Clonal analysis of erythroid progenitors suggests that pegylated interferon a-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by an excess of production of red blood cells driven by mutations in the Janus kinase 2 (JAK2) gene. 1 The most frequent mutation underlying PV is the JAK2 V617F mutation, found in approximately 95% of cases. Rare JAK2 V617F -negative cases have other mutations in JAK2. Recently, TET2 mutations have been found in approximately 15% of PV cases, 2,3 but a clear clinical or prognostic effect of those mutations has not been evidenced. 3 These additional molecular abnormalities can be detected in the founder clone of the disease, but may also be found in a JAK2 V617F -independent clone, or as secondary defects that could participate to the progression of the disease to a myelofibrotic or a blast phase. 4, 5 Interferon a-2a (IFNa) treatment has been shown to induce complete hematologic response, cytogenetic remission or reversion from monoclonal to polyclonal hematopoiesis in studies on few occasional PV patients. In a phase 2 trial of peg-IFNa, we observed a substantial decrease in JAK2 V617F allele burden in peripheral blood granulocytes from 29 patients treated with IFNa alone. 6 In 7 out of 29 patients (24%), JAK2 mutant alleles even became undetectable using an allelespecific PCR assay with a 1% sensitivity (baseline mutant
